Dr. Muto has a special research interest in ovarian cancer occurring in women with a genetic predisposition to the disease. He is Co-Director of the Familial Ovarian Cancer Center in the Cancer Risk and Prevention Service at the Dana-Farber Cancer Institute. In this capacity, he is involved in the clinical management of women with BRCA-1 and BRCA-2 mutations. He is interested in chemoprevention, the efficacy of ultrasound, and CA-125 in early detection and in the role of prophylactic surgery in the prevention of ovarian cancer in these high risk women. His clinical activity supports molecular biologic studies in the etiology of papillary serous carcinoma of the peritoneum, a disease which may occur following prophylactic surgery and which has an impact upon the effectiveness of the operation.